The Experts below are selected from a list of 845742 Experts worldwide ranked by ideXlab platform
Silvana Spadafora - One of the best experts on this subject based on the ideXlab platform.
-
Axillary Lymph Node management in breast cancer with positive sentinel Lymph Node biopsy
World journal of clinical oncology, 2015Co-Authors: Ioannis A Voutsadakis, Silvana SpadaforaAbstract:The surgical treatment of localized breast cancer has become progressively less aggressive over the years. The management of the axillary Lymph Nodes has been modified by the introduction of sentinel Lymph Node biopsy. Axillary dissection can be avoided in patients with sentinel Lymph Node negative biopsies. Based on randomized trials data, it has been proposed that no Lymph Node dissection should be carried out even in certain patients with sentinel Lymph Node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of Lymph Node dissection in breast cancer patients with positive sentinel Lymph Node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered.
Graeme I Murray - One of the best experts on this subject based on the ideXlab platform.
-
increased Lymph Node yield in colorectal cancer is not necessarily associated with a greater number of Lymph Node positive cancers
PLOS ONE, 2014Co-Authors: Aisling Oshea, Omar Aly, Craig Parnaby, M A Loudon, Leslie Samuel, Graeme I MurrayAbstract:The presence of Lymph Node metastasis is a key prognostic factor in colorectal cancer and Lymph Node yield is an important parameter in assessing the quality of histopathology reporting of colorectal cancer excision specimens. This study assesses the trend in Lymph Node evaluation over time in a single institution and the relationship with the identification of Lymph Node positive tumours. It compares the Lymph Node yield of a contemporary dataset compiled from the histopathology reports of 2178 patients who underwent surgery for primary colorectal cancer between 2005 and 2012 with that of a historic dataset compiled from the histopathology reports of 1038 patients who underwent surgery for colorectal cancer at 5 yearly intervals from 1975 to 2000. The mean Lymph Node yield was 14.91 in 2005 rising to 21.38 in 2012. In 2012 92.9% of all cases had at least 12 Lymph Nodes examined. Comparison of the mean Lymph Node yield and proportion of Dukes C cases shows a significant increase (Pearson correlation = 0.927, p = 0.001) in Lymph Node yield while there is no corresponding significant trend in the proportion of Dukes C cases (Pearson correlation = −0.138, p = 0.745). This study shows that there is increasing yield of Lymph Nodes from colorectal cancer excision specimens. However, this is not necessarily associated with an increase number of Lymph Node positive cancers. Further risk stratifying of colorectal cancer requires consideration of other pathological parameters especially the presence of extramural venous invasion and relevant biomarkers.
Robert A Soslow - One of the best experts on this subject based on the ideXlab platform.
-
low volume Lymph Node metastasis discovered during sentinel Lymph Node mapping for endometrial carcinoma
Annals of Surgical Oncology, 2016Co-Authors: Caryn M St Clair, A G Z Eriksson, J A Ducie, Elizabeth L Jewell, Kaled M Alektiar, M L Hensley, Robert A SoslowAbstract:Purpose The aim of this study was to characterize treatment patterns and oncologic outcomes in patients with low-volume Lymph Node metastasis (isolated tumor cells [ITCs] and micrometastasis [MM]) discovered during sentinel Lymph Node (SLN) mapping for endometrial carcinoma.
Ioannis A Voutsadakis - One of the best experts on this subject based on the ideXlab platform.
-
Axillary Lymph Node management in breast cancer with positive sentinel Lymph Node biopsy
World journal of clinical oncology, 2015Co-Authors: Ioannis A Voutsadakis, Silvana SpadaforaAbstract:The surgical treatment of localized breast cancer has become progressively less aggressive over the years. The management of the axillary Lymph Nodes has been modified by the introduction of sentinel Lymph Node biopsy. Axillary dissection can be avoided in patients with sentinel Lymph Node negative biopsies. Based on randomized trials data, it has been proposed that no Lymph Node dissection should be carried out even in certain patients with sentinel Lymph Node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of Lymph Node dissection in breast cancer patients with positive sentinel Lymph Node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered.
Jae Yong Kwak - One of the best experts on this subject based on the ideXlab platform.
-
Erythropoietin Induces Lymph Node Lymphangiogenesis and Lymph Node Tumor Metastasis
Cancer research, 2011Co-Authors: Ae Sin Lee, Duk Hoon Kim, Jung Eun Lee, Yu Jin Jung, Kyung Pyo Kang, Sik Lee, Sung Kwang Park, Jae Yong Kwak, Sang Yong Lee, Suk Tae LimAbstract:Cancer therapy often produces anemia, which is treated with erthropoietin (EPO) to stimulate erythrocyte production. However, concerns have recently arisen that EPO treatment may promote later tumor metastasis and mortality. The mechanisms underlying such effects are unknown, but it is clear that EPO has pleiotropic effects in cell types other than hematopoietic cells. In this study, we investigated how EPO affects Lymphangiogenesis and Lymph Node tumor metastasis in mouse models of breast cancer and melanoma. In these models, EPO increased Lymph Node Lymphangiogenesis and Lymph Node tumor metastasis in a manner associated with increased migration, capillary-like tube formation, and dose- and time-dependent proliferation of human Lymphatic endothelial cells. EPO increased sprouting of these cells in a thoracic duct Lymphatic ring assay. These effects were abrogated by cotreatment with specific inhibitors of phosphoinositide 3-kinase or mitogen-activated protein kinase, under conditions in which EPO increased Akt and extracellular signal-regulated kinase 1/2 phosphorylation. Intraperitoneal administration of EPO stimulated peritoneal Lymphangiogenesis, and systemic treatment of EPO increased infiltration of CD11b(+) macrophages in tumor-draining Lymph Nodes. Finally, EPO increased VEGF-C expression in Lymph Node-derived CD11b(+) macrophages as well as in bone marrow-derived macrophages in a dose- and time-dependent manner. Our results establish that EPO exerts a powerful Lymphangiogenic function and can drive both Lymph Node Lymphangiogenesis and nodal metastasis in tumor-bearing animals.
-
Erythropoietin induces Lymph Node Lymphangiogenesis and Lymph Node tumor metastasis
Cancer Research, 2011Co-Authors: Yu Jin Jung, Kyung Pyo Kang, Sung Kwang Park, Jae Yong KwakAbstract:Cancer therapy often produces anemia, which is treated with erthropoietin (EPO) to stimulate erythrocyte production. However, concerns have recently arisen that EPO treatment may promote later tumor metastasis and mortality. The mechanisms underlying such effects are unknown, but it is clear that EPO has pleiotropic effects in cell types other than hematopoietic cells. In this study, we investigated how EPO affects Lymphangiogenesis and Lymph Node tumor metastasis in mouse models of breast cancer and melanoma. In these models, EPO increased Lymph Node Lymphangiogenesis and Lymph Node tumor metastasis in a manner associated with increased migration, capillary-like tube formation, and dose- and time-dependent proliferation of human Lymphatic endothelial cells. EPO increased sprouting of these cells in a thoracic duct Lymphatic ring assay. These effects were abrogated by cotreatment with specific inhibitors of phosphoinositide 3-kinase or mitogen-activated protein kinase, under conditions in which EPO increased Akt and extracellular signal–regulated kinase 1/2 phosphorylation. Intraperitoneal administration of EPO stimulated peritoneal Lymphangiogenesis, and systemic treatment of EPO increased infiltration of CD11b + macrophages in tumor-draining Lymph Nodes. Finally, EPO increased VEGF-C expression in Lymph Node–derived CD11b + macrophages as well as in bone marrow–derived macrophages in a dose- and time-dependent manner. Our results establish that EPO exerts a powerful Lymphangiogenic function and can drive both Lymph Node Lymphangiogenesis and nodal metastasis in tumor-bearing animals. Cancer Res; 71(13); 4506–17. ©2011 AACR .
